Stifel Nicolaus Boosts Celcuity (NASDAQ:CELC) Price Target to $125.00

Celcuity (NASDAQ:CELC) had its target price hoisted by equities researchers at Stifel Nicolaus from $115.00 to $125.00 in a research note issued on Thursday,Benzinga reports. The firm currently has a “buy” rating on the stock. Stifel Nicolaus’ price objective suggests a potential upside of 17.90% from the company’s current price.

CELC has been the topic of a number of other reports. Jefferies Financial Group boosted their target price on shares of Celcuity from $108.00 to $134.00 and gave the stock a “buy” rating in a research report on Tuesday, December 2nd. Wolfe Research reaffirmed an “outperform” rating and set a $110.00 price target on shares of Celcuity in a report on Thursday, March 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Celcuity in a research note on Wednesday, January 21st. Wells Fargo & Company began coverage on shares of Celcuity in a report on Friday, December 12th. They issued an “overweight” rating and a $126.00 price objective on the stock. Finally, Needham & Company LLC reissued a “buy” rating and issued a $122.00 price objective on shares of Celcuity in a research report on Thursday. Eight analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $109.88.

Celcuity Trading Down 7.7%

NASDAQ CELC opened at $106.02 on Thursday. The company’s 50 day moving average price is $109.49 and its 200 day moving average price is $90.74. The company has a debt-to-equity ratio of 2.74, a quick ratio of 12.26 and a current ratio of 12.26. Celcuity has a one year low of $7.57 and a one year high of $120.32. The firm has a market capitalization of $4.91 billion, a price-to-earnings ratio of -27.97 and a beta of 0.38.

Celcuity (NASDAQ:CELC) last posted its earnings results on Wednesday, March 25th. The company reported ($0.97) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.06) by $0.09. On average, sell-side analysts predict that Celcuity will post -2.62 EPS for the current year.

Insider Activity at Celcuity

In other news, Director David Dalvey sold 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 27th. The shares were sold at an average price of $120.03, for a total transaction of $2,400,600.00. Following the completion of the sale, the director owned 90,000 shares of the company’s stock, valued at approximately $10,802,700. This trade represents a 18.18% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 15.77% of the company’s stock.

Institutional Trading of Celcuity

A number of hedge funds and other institutional investors have recently made changes to their positions in CELC. Ogorek Anthony Joseph NY ADV raised its holdings in Celcuity by 19.7% in the fourth quarter. Ogorek Anthony Joseph NY ADV now owns 662 shares of the company’s stock valued at $66,000 after acquiring an additional 109 shares in the last quarter. US Bancorp DE grew its holdings in Celcuity by 25.4% during the 3rd quarter. US Bancorp DE now owns 706 shares of the company’s stock worth $35,000 after acquiring an additional 143 shares in the last quarter. Intech Investment Management LLC grew its holdings in Celcuity by 1.4% during the 4th quarter. Intech Investment Management LLC now owns 12,983 shares of the company’s stock worth $1,295,000 after acquiring an additional 183 shares in the last quarter. Aristides Capital LLC increased its position in shares of Celcuity by 2.0% in the 4th quarter. Aristides Capital LLC now owns 15,303 shares of the company’s stock worth $1,526,000 after purchasing an additional 303 shares during the last quarter. Finally, EverSource Wealth Advisors LLC increased its position in shares of Celcuity by 1,329.2% in the 4th quarter. EverSource Wealth Advisors LLC now owns 343 shares of the company’s stock worth $34,000 after purchasing an additional 319 shares during the last quarter. Institutional investors own 63.33% of the company’s stock.

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.